Skip to main content
Equibles
JNJ logo

JNJ · Johnson & Johnson

Track JNJ — free

Use JNJ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JNJ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$285.75 +2.23 (+0.79%) At close · Nov 13
S&P 500 member Russell 1000 member Dow 30 member Rebalance outlook locked
Market Cap
$687.89B
Shares
2.41B
Volume · Nov 13 6.33M Avg daily vol (3M) 7.08M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$285.75 Open$285.00 Day$281.68–288.11 52W close$195.25–285.75 Avg vol 30d7.7M Short int17.1M · 0.7% of shares · 2.4d Short vol46% Last earningsOct 13, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 21

Up next

Next earnings call
Jan 20, 2027 Est · unconfirmed · in 9 wks
Q3 2026 earnings call transcript
call held Oct 13, 2026
Play latest call

Latest documents

2026
Oct 21
Quarterly report 10-Q FY2026 Q3, ended Sep 27
Quarterly report for FY2026 Q3

Johnson & Johnson reported fiscal nine months 2026 worldwide sales of $74.8 billion, up 7.4%; Q3 earnings before taxes were $34.0 million, including a $5.5 billion talc ovarian litigation resolution charge and $1.0 billion of Firefly Bio, Inc. acquisition expense.

Revenue $25.4B ▲ 5.9% Net income $210M ▼ 95.9% Diluted EPS $0.09 ▼ 95.8%
Read from the MD&A section
Oct 13
Earnings call
Q3 2026 earnings call

Johnson & Johnson raised full-year operational sales growth guidance to 6.7% to 7.1%, with operational sales of $100.7 billion at the midpoint, and adjusted operational EPS guidance of ten dollars and ninety-five cents to eleven dollars and five cents.

Oct 13
Current report 8-K
Financial results

Johnson & Johnson reported third-quarter sales of $25.4 Billion, up 5.9%, and raised estimated 2026 reported sales to $101.2 Billion at midpoint and adjusted EPS to $11.10 at midpoint.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$99.33B
Trailing 12 months
Net income (TTM)
$16.09B
Trailing 12 months
Revenue growth YoY
+5.9%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
43.4
Trailing earnings · reciprocal yield 2.3%
FCF yield
3.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$27.42B
Latest balance sheet
Dividend yield
1.8%
Trailing 12 months
Shares change YoY
+0.8%
Year over year · more shares
Price change (1Y)
+46.4%
Trailing year
Short interest
0.7%
Latest settlement · 2.4 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲5.3% $22.52B $3.43B '24 Q4* ▲2.4% $21.89B $11.00B '25 Q1 ▲5.8% $23.74B $5.54B '25 Q2 ▲6.8% $23.99B $5.15B '25 Q3 ▲9.1% $24.56B $5.12B '25 Q4* ▲9.9% $24.06B $5.24B '26 Q1 ▲6.6% $25.31B $5.53B '26 Q2 LATEST ▲5.9% $25.40B $210.00M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Oct 13, 2026
Q3 FY26

TL;DR. Johnson & Johnson reported Q3 sales of $25.4 billion with operational growth of 6.0% and raised full-year 2026 guidance, but GAAP EPS collapsed to $0.09 on talc litigation and M&A costs, MedTech growth lagged at 2.5% with management signaling dissatisfaction, and Innovative Medicine margin contracted sharply.

Bullish
  • + Q3 sales exceeded $25 billion, surpassing $100 billion in annual revenue for the first time
  • + Innovative Medicine delivered strong 7.9% operational growth led by Darzalex, Carvykti, Tremfya, and Rybrevant/Lazcluze
  • + Tremfya surged 68.2% on IBD launch momentum with 4 points of share growth in UC and Crohn's
  • + Rybrevant plus Lazcluze delivered 63.5% growth with strong first/second-line share gains
Bearish
  • − GAAP EPS collapsed to $0.09 from $2.12 due to ~$7 billion in talc litigation and Firefly/Sail charges
  • − Innovative Medicine segment margin compressed from 44.3% to 35.4% on Firefly IPR&D and Sail costs
  • − Stelara declined 54% from biosimilar competition and novel class shift
  • − Abiomed sales declined 1.5% globally on study-related headwinds outside the U.S.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Research

our published analysis of this company

Mentioned in fund letters

Equibles Rating

blended score · not investment advice
Overall
Strong Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very Low
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +14%
above
Price vs 50-day avg +7%
above
RSI (14) 66
neutral
MACD trend Positive
52-week position 100%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +12%
trailing
6-month return +24%
trailing
YTD return +38%
this year
Relative strength +24%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $267 › 200d $250 — 50d above 200d
Institutional flow Accumulating
4,330 of 4,738 funds reported for Sep 30 · net +25.1M sh shares · +134 new
Insider flow Distributing
Net -$16.9M over 90 days · 100% sells
Short interest Rising
0.71% of shares out · ▲ +1.8% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
4,738 holders — near 3-yr high, broad support
Squeeze score 48
elevated · 0–100
Fundamentals
Excellent
Revenue growth +6%
Y/Y
Gross margin 68%
contracting
EPS growth +91%
Y/Y
Free cash flow $19.7B
Valuation P/E 43.4
below peers
Buyback $5.0B
authorized
Balance sheet $28.2B
net debt
Quant / Vol
risk profile
Very Low
Volatility 21%
annualized · 1-yr
Max drawdown −11%
past year
ATR 2.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 4
Latest guidance · from the Earnings Call filed Oct 13, 2026
full year
Full year free cash flow guidance $21B
full year 2026
Express participation 95%
full year adjusted earnings per share next year
Combined dilutive impact Non-GAAP $1.36
this year
IPR&D dilution 64%
Previous outlook earlier release · from the 8-K filed Jan 21, 2026

Still-open targets the latest release did not restate under the same label.

Estimated Reported Sales · January 2026 $100B – $101B
Operational Sales · January 2026 $99.5B – $100.5B
Guided vs delivered · last 4 settled
Estimated Reported Sales Full-year 2025
guided $93.5B – $93.9B
$94.19B Beat +0.5%
Estimated Reported Sales 2023 full-year
guided $97.9B – $98.9B
$85.16B Miss −13.5%
Estimated Reported Sales Full-Year 2022
guided $93B – $93.5B
$79.99B Miss −14.2%
Earnings per share 2022
guided $0.20
$6.73 Beat +3265.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+14% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
66 Neutral
MACD trend
Positive Bullish
52-week position
100% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $267 › 200d $250 — 50d above 200d
Institutional flow Accumulating
4,330 of 4,738 funds reported for Sep 30 · net +25.1M sh shares · +134 new
Insider flow Distributing
Net -$16.9M over 90 days · 100% sells
Short interest Rising
0.71% of shares out · ▲ +1.8% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
4,738 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $195 Now $286 · 100% Range high $286
vs 200-day avg +14% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EPS (diluted) non-GAAP $2.59 Q3 2026 —
Adjusted Net Earnings non-GAAP $6.34B Q3 2026 —
GAAP → non-GAAP reconciliation
GAAP Net Earnings, after tax- as reported $210M
+$5.52B Litigation related
+$1.24B Intangible Asset Amortization expense
+$195M Restructuring related
+$369M Orthopaedics separation related
-$34M Acquisition, integration and divestiture related
+$10M (Gains)/losses on securities
+$339M IPR&D impairments
+$0M Other
-$1.68B Tax impact on special item adjustments
+$168M Tax legislation and other tax related
= Adjusted Net Earnings $6.34B
Adjusted Operational Sales non-GAAP 6.1% Q3 2026 —
Free Cash Flow non-GAAP $15.1B Q3 2026 YTD —
Innovative Medicine operational sales growth non-GAAP 7.9% Q3 2026 —
MedTech operational sales growth non-GAAP 2.5% Q3 2026 —
Operational Sales non-GAAP 6% Q3 2026 —
Cardiovascular franchise operational sales change 3.1% fiscal second quarter of 2026 filing —
Dividends per share $1.34 fiscal second quarter of 2026 filing —
International Innovative Medicine sales change 6% fiscal second quarter of 2026 filing —
International MedTech sales change 5.2% fiscal second quarter of 2026 filing —
Net debt position $28.2B fiscal second quarter of 2026 filing —
Neuroscience operational sales change 13.4% fiscal second quarter of 2026 filing —
Oncology operational sales change 16.1% fiscal second quarter of 2026 filing —
Orthopaedics franchise operational sales change 4.2% fiscal second quarter of 2026 filing —
Pulmonary Hypertension operational sales change 2.2% fiscal second quarter of 2026 filing —
Surgery franchise operational sales change 2.3% fiscal second quarter of 2026 filing —
U.S. Innovative Medicine sales change 8.9% fiscal second quarter of 2026 filing —
Vision franchise operational sales change 5.6% fiscal second quarter of 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
JNJ
Johnson & Johnson
this stock
$687.89B +38.1% +6.0% 43.4 0.7%
LLY
ELI LILLY & Co
 $1.36T +34.3% +44.7% 46.9 0.8%
ABBV
AbbVie Inc.
 $521.50B +29.1% +8.6% 50.8 0.9%
MRK
Merck & Co., Inc.
 $364.26B +40.4% +1.3% 152.3 1.1%
NVS
Novartis AG
 $303.12B +16.4% — — 0.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
4,832
% held
77.3%
Reported
4,330 of 4,738
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,727
View
Short & Settlement
Short Interest Rising
Shares short
17.1M
Days to cover
2.4d
Change
+301.6K sh
View
Short Volume
Short vol %
46%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
157
Value
$39.0K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
49.8%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$16.9M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Sell
Member
Thomas H. Kean
Amount
$1.0K–$15.0K
Traded
Sep 30, 2026
View
Financials
Financials
Revenue (FY)
$94.2B
Net income (FY)
$26.8B
EPS diluted
$11.03
View
Buybacks
Authorized
$5.0B
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 21, 2026
This year
23

Johnson & Johnson reported fiscal nine months 2026 worldwide sales of $74.8 billion, up 7.4%; Q3 earnings before taxes were $34.0 million, including a $5.5 billion talc ovarian litigation resolution charge and $1.0 billion of Firefly Bio, Inc. acquisition expense.

View
Proposed Sales
Value
$3.7M
Shares
13.1K
Filed
Nov 12, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 13, 2026
View
Investor Relations
Latest news
Johnson & Johnson Announces CAPLY…
Published
Nov 10, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
JNJ +3.5% +11.8% +24.1% +4.6% +38.1%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +0.9% +13.0% +23.6% +4.8% +27.5%

Capital returns

Latest dividend
$1.34 / share · ex Aug 25, 2026
Declared · upcoming
$1.34 / share · ex Nov 24, 2026
Raised 3.1%
Paid (TTM)
$5.28 / share · 4 payouts
Dividend yield (TTM, derived)
1.85%
Full dividend history
Buyback program · as of Sep 14, 2022
Authorized
$5.00B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 200406 CUSIP 478160104 13F (30d) 3735 filings 3539 filers Visit website Investor relations